Lexeo (LXEO) CFO Louis Tamayo Receives 54,750-Share Award

What Happened

• Louis Edward Tamayo, CFO of Lexeo Therapeutics (LXEO), was granted a derivative award of 54,750 shares on 2026-09-24. The reported acquisition price is $0.00, and the filing lists the transaction as an award/grant (derivative), not a market purchase or sale.

Key Details

• Transaction date: 2026-09-24; Filing date: 2026-09-28 (covering the 9/24 grant).
• Reported consideration: $0.00 (derivative award).
• Shares involved: 54,750 shares granted.
• Shares owned after transaction: Not specified in the filing.
• Footnote (vesting): 25% of the shares underlying the option vest and become exercisable on Sept 24, 2027, with the remaining shares vesting in monthly 1/48th installments thereafter, subject to continuous service.
• No indication in the filing that shares were sold or exercised immediately; this is a grant, not a cash transaction.

Context

• This was a derivative grant (e.g., stock option/RSU-style award) with a multi-year vesting schedule. Such grants typically align executive compensation with long-term performance; they do not represent an immediate market purchase or sale of stock. The filing does not show any immediate monetization (no exercise or sale reported).